Arvinas (ARVN) and Pfizer (PFE) on Tuesday reported "encouraging" preliminary data from an ongoing phase 1b trial of their vepdegestrant drug candidate in combination with Eli Lilly's (LLY) abemaciclib kinase inhibitor in patients with a form of breast cancer.
Trial results from 16 patients with locally advanced or metastatic estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer demonstrated a tolerable safety profile for the combination of 200 milligrams of vepdegestrant daily with 150 milligrams of abemaciclib twice daily.
The drug combination showed a clinical benefit rate of 62.5% and an overall response rate of 26.7% among breast cancer patients previously treated with a CDK4/6 inhibitor, the companies said.
Arvinas shares were down more than 2% in recent trading, while Pfizer was off by about 1%.
Price: 25.00, Change: -0.08, Percent Change: -0.34
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。